Merck KGAA gave a look at the new data and analyses behind its renewed push for approval of the multiple sclerosis candidate cladribine at the recent 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2016).
The purine nucleotide analog was the subject of an ample number of presentations at the conference in London, including analyses...






